Condition Results Operations The following commentary read conjunction consolidated financial statements accompanying notes EXECUTIVE OVERVIEW Description Company Business Segments Baxter International Inc subsidiaries provides broad portfolio essential renal hospital products including acute chronic dialysis sterile IV solutions infusion systems devices parenteral nutrition therapies premixed oncolytic injectables biosurgery products anesthetics drug reconstitution systems pharmacy automation software services The company global footprint critical nature products services play key role expanding access healthcare emerging developed countries These products used hospitals kidney dialysis centers nursing homes rehabilitation centers doctors offices patients home physician supervision Separation Baxalta Incorporated On July 1 2015 Baxter completed distribution approximately 80.5 outstanding common stock biopharmaceuticals business Baxalta Incorporated Baxalta Baxter stockholders Distribution As result separation operating results Baxalta reflected discontinued operations years ended December 31 2016 2015 2014 Refer Note 2 Item 8 additional information regarding separation Baxalta Unless otherwise stated financial results herein reflect continuing operations Segments Baxter operates two reportable segments Hospital Products Renal Refer Note 14 Item 8 additional information regarding company segments The segments description products services follows The Hospital Products business manufactures sterile intravenous IV solutions administration sets premixed drugs drug-reconstitution systems pre-filled vials syringes injectable drugs parenteral nutrition therapies infusion pumps inhalation anesthetics biosurgery products The business also provides products services related pharmacy compounding drug formulation sterile IV solutions infusion systems devices parenteral nutrition therapies premixed oncolytic injectables biosurgery products anesthetics drug reconstitution systems pharmacy automation software services The Renal business offers comprehensive portfolio meet needs patients end-stage renal disease irreversible kidney disease acute kidney injuries including technologies therapies peritoneal dialysis PD hemodialysis HD continuous renal replacement therapy CRRT additional dialysis services Baxter approximately 48,000 employees conducts business 100 countries The company generates approximately 60 revenues outside United States maintains approximately 50 manufacturing facilities 100 distribution facilities United States Europe Asia-Pacific Latin America Canada Financial Results Baxter global net sales totaled 10.2 billion 2016 increase 2 2015 including unfavorable foreign currency impact two percentage points International sales totaled 5.9 billion 2016 decrease 1 compared 2015 including unfavorable foreign currency impact four percentage points Sales United States totaled 4.3 billion 2016 increase 6 compared 2015 Baxter income continuing operations 2016 totaled 5.0 billion 9.01 per diluted share compared 393 million 0.72 per diluted share prior year Income continuing operations 2016 included special items resulted net increase income continuing operations 3.9 billion 7.05 per diluted share Income continuing operations 2015 included special items resulted net reduction income continuing operations 362 million 0.66 per diluted share The company special items discussed Results Operations section 18 Baxter financial results included R&D expenses totaling 647 million 2016 reflects company focus balancing increased investments support company new product pipeline efforts optimize overall R&D spending continuous evaluation portfolio The company financial position remains strong operating cash flows continuing operations totaling 1.6 billion 2016 The company continued execute disciplined capital allocation framework designed optimize stockholder value creation reinvestment businesses dividends targeted share repurchases well acquisitions business development initiatives discussed Strategic Objectives section Capital investments totaled 719 million 2016 company continues invest across businesses support future growth including additional investments support new existing product capacity expansions The company investments capital expenditures 2016 focused projects improve production efficiency enhance manufacturing capabilities support strategy geographic expansion select investments growing markets The company also continued return value stockholders form dividends During 2016 company paid cash dividends shareholders totaling 268 million Additionally 2016 company repurchased 17.8 million shares cash repurchases equity-for-equity exchange Retained Shares outstanding Baxter shares Strategic Objectives Baxter continues focus several key objectives successfully execute long-term strategy achieve sustainable growth deliver enhanced stockholder value Baxter diversified broad portfolio medical products treat life-threatening acute chronic conditions global presence core components company strategy achieve objectives The company focused three strategic factors part pursuit industry leading performance optimizing core portfolio globally operational excellence focused streamlining cost structure enhancing operational efficiency following disciplined balanced approach capital allocation Optimizing Core Portfolio Globally Baxter categorized product portfolio four strategic business groupings Those groupings include core growth core return capital maintain manage differently strategic bets Within core growth grouping Baxter looks invest long-term higher margin growth Baxter looks optimize return investment maintain enhance market position core return capital products Maintain manage differently products Baxter looks sustain reposition underlying investment Finally strategic bet grouping includes products Baxter evaluating market position investment strategy These products cover mature emerging markets While Baxter made initial assignment product categories one business groupings described Baxter continues evaluate product category placement light shifting market dynamics company priorities may reassign product category different business grouping time time As part portfolio review Baxter seeks optimize position product areas company stable profitable business model identify alter investments products reached end life cycles respect market positions evolved unfavorably In course Baxter expects continue reallocate capital promising opportunities business groupings described As part strategy Baxter shifting investments drive innovation compelling opportunities serve patients healthcare professionals advancing business accelerate pace bringing advances market Baxter midst launching 100 products 2020 areas chronic acute renal care smart pump technology hospital pharmaceuticals nutritionals surgical sealants These comprise mix entirely new offerings marked improvements existing technologies expansion current products new geographies Operational Excellence As part pursuit improved margin performance Baxter working optimize cost structure consistent emergence stand-alone medical products company critically assessing optimal support levels light company ongoing portfolio optimization efforts The company intends continue actively manage cost structure help ensure committing resources highest value uses Such high value activities include supporting innovation building portfolio expanding patient access accelerating growth company stockholders 19 Baxter undertaken comprehensive review aspects operations already begun implement changes line business goals Maintaining Disciplined Balanced Capital Allocation Baxter capital allocation strategies include following reinvest business funding opportunities positioned deliver sustainable growth support company innovation efforts improve margin performance return capital stockholders stock dividends meaningfully increase earnings growth targeted share repurchases identify pursue accretive M&A opportunities generate returns targeted thresholds Responsible Corporate Citizen The company strives continued growth profitability furthering focus acting responsible corporate citizen At Baxter sustainability means creating lasting social environmental economic value addressing needs company wide-ranging stakeholder base Baxter comprehensive sustainability program focused areas company uniquely positioned make positive impact Priorities include providing employees safe healthy inclusive workplace fostering culture drives integrity strengthening access healthcare enhancing math science education driving environmental performance across product life cycle including development manufacturing transport Baxter Baxter International Foundation provide financial support product donations support critical needs assisting underserved communities providing emergency relief countries experiencing natural disasters Throughout 2016 company continued implement range water conservation strategies facility-based energy saving initiatives In area product stewardship life cycle management Baxter pursuing efforts sustainable design reduced packaging Baxter also responding challenges climate change innovative greenhouse gas emissions-reduction programs shifting less carbon-intensive energy sources manufacturing transport Additionally company developed new long-term goals drive continued environmental stewardship creating healthier sustainable communities Baxter employees work live Risk Factors The company ability sustain long-term growth successfully execute strategies discussed depends part company ability manage within increasingly competitive regulated environment address risk factors described Item 1A Annual Report Form 10-K 20 RESULTS OF OPERATIONS Special Items The following table provides summary company special items related impact line item company results continuing operations 2016 2015 2014 years ended December 31 millions 2016 2015 2014 Gross Margin Intangible asset amortization expense 163 158 168 Business optimization items1 156 38 11 Intangible asset impairment2 51 Separation-related costs3 1 Product-related items4 18 28 64 Total Special Items 353 168 221 Impact Gross Margin Ratio 3.5 pts 1.7 pts 2.1 pts Marketing Administrative Expenses Business optimization items1 173 152 115 Separation-related costs3 53 110 11 Product-related items4 4 Branded Prescription Drug Fee5 3 Total Special Items 226 262 133 Impact Marketing Administrative Expense Ratio 2.3 pts 2.6 pts 1.2 pts Research Development Expenses Business optimization items1 80 13 2 Separation-related costs3 1 Total Special Items 80 14 2 Other Income Expense Net Business optimization items1 3 25 Net realized gains Retained Shares transactions6 4,391 Loss debt extinguishment7 149 130 Reserve items adjustments8 52 1 Business development items9 20 Tax matter10 9 Total Special Items 4,233 55 26 Income Tax Expense Impact special items10 314 137 137 Total Special Items 314 137 137 Impact Effective Tax Rate 22.1 pts 10.4 pts 12.8 pts Intangible asset amortization expense identified special item facilitate evaluation current past operating performance similar management internally assesses performance Additional special items identified highly variable difficult predict size may substantially impact company reported operations period Management believes providing separate impact items company results accordance generally accepted accounting principles GAAP United States may provide complete understanding company operations facilitate fuller analysis company results operations particularly evaluating performance one period another This information considered addition substitute information prepared accordance GAAP 1 In 2016 2015 2014 company results impacted costs associated company execution certain strategies optimize organization global cost structure global basis These actions included streamlining company international operations rationalizing manufacturing facilities reducing general administrative infrastructure re-aligning certain R&D activities cancelling certain R&D programs The company recorded net business optimization charges 409 million 200 million 131 million 2016 2015 2014 respectively The company results 2016 included net charge 285 million related restructuring activities 65 million costs implement business optimization programs primarily included external consulting project employee costs 33 million accelerated depreciation associated facilities closed 26 million Gambro integration costs The 285 million 21 restructuring charges included net 180 million employee termination costs 54 million costs related discontinuance VIVIA home hemodialysis development program 47 million asset impairment charges related acquired in-process R&D facility closure costs 4 million exit costs The company results 2015 included net charge 127 million related restructuring activities 73 million Gambro integration costs The 127 million net restructuring charges included net 91 million employee termination costs 20 million intangible asset impairment 16 million asset impairments exit costs The company results 2014 included 144 million Gambro integration costs net benefit 13 million adjustments reserves longer probable utilized Refer Note 7 Item 8 information regarding charges related reserves 2 The company results 2016 included 51 million asset impairment primarily related developed technology 3 The company results 2016 2015 2014 included costs related Baxalta separation 54 million 111 million 11 million respectively 4 The company results 2016 2015 included net benefit 18 million 28 million respectively primarily related adjustments COLLEAGUE SIGMA SPECTRUM infusion pump reserves The company results 2014 included charges net reversals 68 million primarily related product remediation efforts SIGMA SPECTRUM infusion pump Refer Note 7 Item 8 information regarding charges related reserves 5 The company results 2014 included charge 3 million account additional year Branded Prescription Drug Fee accordance final regulations issued third quarter 2014 Internal Revenue Service 6 The company results 2016 included net realized gains 4.4 billion related debt-for-equity exchanges company retained shares Baxalta certain indebtedness exchange retained shares Baxalta Baxter shares contribution retained shares Baxalta Baxter U.S pension fund 7 The company results 2016 included net debt extinguishment loss totaling 149 million related March 2016 debt-for-equity exchange certain company indebtedness certain debt redemptions The company results 2015 included loss 130 million related July 2015 tender offer certain outstanding indebtedness Refer Note 8 Item 8 additional information 8 The company results 2015 included income 52 million related litigation settlement Baxter beneficiary The company results 2014 included income 1 million related third-party recoveries reversals prior litigation reserves 9 The company results 2015 included benefit 20 million relating reversal contingent consideration milestone liabilities Refer Note 5 Item 8 information regarding company acquisitions arrangements 10 The company results 2016 included net after-tax benefit 10 million related settlement income tax matter company non-wholly owned joint venture Turkey This amount comprised 19 million included income tax expense offset 9 million non-controlling interest recorded income Net Sales Percent change At actual currency rates At constant currency rates years ended December 31 millions 2016 2015 2014 2016 2015 2016 2015 Renal 3,855 3,789 4,172 2 9 5 1 Hospital Products 6,308 6,179 6,547 2 6 4 1 Total net sales 10,163 9,968 10,719 2 7 4 1 Percent change At actual currency rates At constant currency rates years ended December 31 millions 2016 2015 2014 2016 2015 2016 2015 United States 4,259 4,001 3,999 6 0 6 0 International 5,904 5,967 6,720 1 11 3 2 Total net sales 10,163 9,968 10,719 2 7 4 1 Net sales year ended December 31 2016 increased 2 actual currency rates 4 constant currency basis Net sales year ended December 31 2015 decreased 7 actual currency rates increased 1 constant currency basis 22 Foreign currency unfavorably impacted net sales two percentage points 2016 compared prior year principally due strengthening U.S dollar relative British Pound Mexican Peso Colombian Peso Chinese Yuan well currencies partially offset weakening U.S dollar relative Japanese Yen Foreign currency unfavorably impacted net sales eight percentage points 2015 compared 2014 principally due strengthening U.S Dollar relative Euro Australian Dollar Colombian Peso certain currencies The comparisons presented constant currency rates reflect comparative local currency sales prior year foreign exchange rates This measure provides information change net sales assuming foreign currency exchange rates changed prior current period The company believes non-GAAP measure change net sales constant currency rates used conjunction GAAP measure change net sales actual currency rates may provide complete understanding company operations facilitate fuller analysis company results operations particularly evaluating performance one period another Franchise Net Sales Reporting The Renal segment includes sales company peritoneal dialysis PD hemodialysis HD continuous renal replacement therapies CRRT additional dialysis services The Hospital Products segment includes four commercial franchises Fluid Systems Integrated Pharmacy Solutions Surgical Care Other Fluid Systems includes sales company IV therapies infusion pumps administration sets Integrated Pharmacy Solutions includes sales company premixed oncology drug platforms nutrition products pharmacy compounding services Surgical Care includes sales company inhaled anesthesia critical care products well biological products medical devices used surgical procedures hemostasis tissue sealing adhesion prevention Other includes sales primarily company pharmaceutical partnering business The following summary net sales commercial franchise Percent change At actual currency rates At constant currency rates years ended December 31 millions 2016 2015 2014 2016 2015 2016 2015 Total Renal net sales 3,855 3,789 4,172 2 9 5 1 Fluid Systems 2,300 2,106 2,129 9 1 11 6 Integrated Pharmacy Solutions 2,245 2,297 2,535 2 9 0 2 Surgical Care 1,321 1,323 1,373 0 4 1 3 Other 442 453 510 2 11 2 5 Total Hospital Products net sales 6,308 6,179 6,547 2 6 4 1 Net sales Renal segment increased 2 2016 2015 decreased 9 2015 2014 These amounts include unfavorable foreign currency impact three percentage points 2016 10 percentage points 2015 Sales increased 5 constant currency basis 2016 driven continued global growth patients new product launches improved pricing United States PD business PD contributed approximately two percentage points growth rate 2016 In addition increased sales company CRRT treat acute kidney injury contributed two percentage points growth rate 2016 Renal net sales expected negatively impacted 2017 approximately 50 million compared 2016 due certain international strategic market exits Sales increased 1 constant currency basis 2015 driven continued growth number PD patients globally contributed approximately three percentage points strong demand acute business These factors partially offset lower sales chronic in-center HD business resulting decision forgo certain lower margin sales opportunities increased austerity measures Western Europe competitive pressures dialyzers 23 Net sales Hospital Products segment increased 2 2016 decreased 6 2015 Foreign currencies unfavorable impact two percentage points 2016 seven percentage points 2015 Hospital Products net sales expected negatively impacted 2017 approximately 50 million compared 2016 due certain international strategic market exits Excluding impact foreign currency principal drivers impacting 2016 net sales growth following In Fluid Systems franchise sales increased 11 2016 constant currency basis driven favorable pricing volume IV solutions increased sales SIGMA SPECTRUM pump related sets United States Sales increased 6 2015 constant currency basis driven increased sales infusion system products contributed approximately four percentage points including relaunch SIGMA Spectrum infusion pump United States Puerto Rico Canada 2015 Additionally sales growth 2015 impacted favorable pricing volume United States company IV therapies contributed approximately one percentage point In Integrated Pharmacy Solutions franchise sales flat 2016 constant currency basis driven global demand company nutritional therapies contributing approximately one percentage point 2016 demand company international pharmacy compounding services contributed approximately one percentage point 2016 These increases offset lower U.S sales company pharmacy injectable products government PROTOPAM orders 2015 reoccur 2016 contributing approximately one percentage point decline In addition U.S sales cyclophosphamide generic oncology drug approximately 210 million 270 million 2016 2015 respectively contributed approximate three percentage point decline 2016 The company expects significant decline U.S sales cyclophosphamide 2017 due additional competition market Sales decreased 2 2015 constant currency basis driven decreased sales cyclophosphamide following competitor entering U.S market November 2014 contributed approximately six percentage points U.S sales cyclophosphamide 2014 approximately 450 million This decline offset increase revenues pharmacy compounding services increased demand company nutritional therapies pharmacy injectable products including approximately 40 million sales PROTOPAM contributed two percentage points In Surgical Care franchise sales increased 1 2016 constant currency basis driven increased demand international anesthesia products Sales increased 3 2015 constant currency basis driven strong global demand company portfolio anesthetics products contributed three percentage points offset partially lower sales select non-core biosurgery products In Other franchise sales decreased 2 2016 constant currency basis compared 2015 driven lower demand products manufactured Baxter behalf one pharmaceutical partners The company also recognized revenue 39 million 2016 compared 37 million 2015 related company manufacturing supply agreement Baxalta Sales decreased 5 2015 constant currency basis compared 2014 driven one company pharmaceutical partners electing self-manufacture products previously contract manufactured Baxter This loss revenue partially offset increased sales related company manufacturing supply agreement Baxalta Gross Margin Expense Ratios Change years ended December 31 percent net sales 2016 2015 2014 2016 2015 Gross margin 40.4 41.6 42.7 1.2 pts 1.1 pts Marketing administrative expenses 27.0 31.0 30.9 4.0 pts 0.1 pts Gross Margin The special items previously identified unfavorable impact 3.5 1.7 2.1 percentage points gross margin ratio 2016 2015 2014 respectively Refer Special Items section additional detail Excluding impact special items gross margin ratio increased 0.6 percentage points 2016 The gross margin ratio impacted positive sales mix improved pricing select areas portfolio favorable manufacturing performance offset reduced sales cyclophosphamide United States foreign exchange Excluding impact special items gross margin ratio 2015 unfavorably impacted decreased sales cyclophosphamide United States partially offset improved product mix Renal segment 24 Marketing Administrative Expenses The special items identified unfavorable impact 2.3 2.6 1.2 percentage points marketing administrative expenses ratio 2016 2015 2014 respectively Refer Special Items section additional detail Excluding impact special items marketing administrative expense ratio decreased 3.7 percentage points 2016 impacted reduced pension expense well benefits company actions taken rebase cost structure continued focus expense management addition reduction expense transition services agreement Baxalta Excluding impact special items marketing administrative expense ratio 2015 impacted benefits company business optimization actions company resets cost structure reduced discretionary spending benefited certain costs charged Baxalta transition services agreement These benefits partially offset increased bad debt expense emerging markets Pension Other Postemployment Benefit Plan Expense Expense related company pension postemployment benefit plans decreased 111 million 2016 primarily due change approach estimating employer service interest costs 706 million voluntary non-cash contribution US qualified plan using Retained Shares Pension postemployment benefit plan expense increased 8 million 2015 primarily due decrease discount rate Business Optimization Items Beginning second half 2015 company initiated actions transform company cost structure enhance operational efficiency These efforts include restructuring organization optimizing manufacturing footprint R&D operations supply chain network employing disciplined cost management centralizing streamlining certain support functions Through December 31 2016 company incurred cumulative pretax costs 407 million related actions The costs consisted primarily employee termination costs implementation costs accelerated depreciation The company expects incur additional pretax costs approximately 390 million capital expenditures 90 million related initiatives end 2018 These costs primarily include employee termination costs implementation costs accelerated depreciation The company expects approximately 10 percent charges non-cash These actions aggregate expected provide future annual pretax savings approximately 860 million The savings actions impact cost sales marketing administrative expenses R&D expenses The company estimates actions taken December 31 2016 resulted approximately 343 million savings 2016 Approximately 85 percent expected annual pretax savings expected realized end 2018 remainder end 2020 In addition programs company recorded additional net business optimization charges 125 million 2016 These charges primarily include employee termination costs contract termination costs asset impairments Gambro integration costs Approximately 40 costs non-cash The company anticipate incurring additional costs related programs future The actions aggregate expected provide future annual pretax savings approximately 19 million The savings actions impact cost sales marketing administrative expenses R&D expenses The company estimates actions taken December 31 2016 resulted approximately 8 million savings current period The remaining pretax savings expected realized programs substantially completed end 2017 Refer Note 7 Item 8 additional information regarding company business optimization initiatives Research Development Percent change years ended December 31 millions 2016 2015 2014 2016 2015 Research development expenses 647 603 610 7 1 percent net sales 6.4 6.0 5.7 0.4 pts 0.3 pts The special items identified unfavorable impact 80 million 14 million 2 million 2016 2015 2014 respectively 25 Excluding impact special items R&D expenses decreased 4 2016 primarily due optimization infrastructure exit certain programs impact foreign currency R&D expenses 2015 declined company worked balance increased investments efforts optimize overall R&D expenditures Net Interest Expense Net interest expense 66 million 126 million 145 million 2016 2015 2014 respectively The decrease 2016 principally driven lower outstanding debt result first quarter 2016 debt-for-equity exchanges reduced coupon rates resulting third quarter 2016 debt issuance partially offset lower capitalized interest compared 2015 The decrease 2015 principally driven debt tender offer completed July 2015 maturity 600 million 4.625 senior unsecured notes March 2015 partially offset higher interest company short term revolving credit facility lower capitalized interest lower income interest rate hedging activities Refer Note 3 Item 8 summary components net interest expense 2016 2015 2014 Other Income Expense Net Other income expense net income 4.3 billion 2016 income 105 million 2015 expense 21 million 2014 Current year results included net realized gains 4.4 billion Retained Shares transactions dividend income 16 million Retained Shares 28 million income related foreign currency fluctuations principally relating intercompany receivables payables monetary assets denominated foreign currency These income items partially offset net debt extinguishment losses 153 million The 2015 results driven primarily 52 million income related favorable litigation settlement 38 million income sale available-for-sale securities 113 million income related foreign currency fluctuations principally relating intercompany receivables payables monetary assets denominated foreign currency partially offset 130 million loss extinguishment debt related July 2015 debt tender offer Segment EBITDA The company uses income continuing operations net interest expense income tax expense depreciation amortization expense Segment EBITDA segment basis make resource allocation decisions assess ongoing performance company business segments Refer Note 17 Item 8 additional details regarding company segments The following summary significant factors impacting segments financial results Renal Segment EBITDA 703 million 566 million 666 million 2016 2015 2014 respectively The increase 2016 primarily driven increased sales lower marketing administrative expenses cost savings realized company business optimization programs continued focus expense management This partially offset unfavorable foreign currency fluctuations incremental manufacturing quality costs higher allocated R&D costs EBITDA declined 2015 due unfavorable foreign currency fluctuations impairment certain intangible assets investments certain quality programs manufacturing capabilities partially offset efficiencies related integration Gambro business Hospital Products Segment EBITDA 2.3 billion 2.0 billion 2.2 billion 2016 2015 2014 respectively The increase 2016 driven increased sales favorable manufacturing performance lower allocated R&D costs lower marketing administrative expenses cost savings realized company business optimization programs continued focus expense management This growth partially offset unfavorable foreign currency fluctuations EBITDA 2015 impacted primarily unfavorable foreign currency fluctuations decreased sales higher margin cyclophosphamide product This offset reduction costs 2014 related manufacturing inefficiencies quality costs Corporate Certain income expense amounts allocated segment These amounts detailed table Note 17 Item 8 primarily include net interest expense foreign exchange fluctuations principally relating intercompany receivables payables loans denominated foreign currency majority foreign currency hedging activities corporate headquarters costs international global support costs stock compensation expense non-strategic investments related income expense certain employee benefit plan costs well certain nonrecurring gains losses charges business optimization asset impairments 26 Income Taxes Effective Income Tax Rate The effective income tax rate continuing operations 0.2 2016 8.2 2015 6.7 2014 The company anticipates effective income tax rate continuing operations calculated accordance GAAP approximately 21.5 2017 excluding impact tax windfalls deficiencies attributable stock compensation exercises well additional audit developments special items The company effective tax rate differs U.S federal statutory rate year due certain operations subject tax incentives state local taxes foreign taxes different U.S federal statutory rate The average foreign effective tax rate international pre-tax income continuing operations 25.2 27.5 24.1 years ended December 31 2016 2015 2014 respectively The company average foreign effective tax rate lower U.S federal statutory rate result impact tax incentives Puerto Rico Switzerland certain tax jurisdictions outside United States well foreign earnings tax jurisdictions lower statutory rates United States Adversely impacting foreign rate foreign loss-generating operations receive tax benefits due losses resulting contributing need valuation allowance In addition discussed company effective income tax rate impacted year discrete factors events Refer Note 15 Item 8 information regarding company income taxes Factors impacting company effective tax rate 2016 included tax-free net realized gains first second quarter associated exchanges Baxalta Retained Shares company debt company shares well tax-free net realized gains associated contribution Baxalta Retained Shares company pension plan Additionally income tax rate 2016 favorably impacted tax benefits partially settling IRS 2008-2013 income tax audit settling German 2008-2011 income tax audit resolution uncertain tax positions related company Turkish joint venture transfer pricing matters partial settlement interest expense deductions related company acquisition Gambro Factors adversely impacting company effective tax rate 2015 included charges related contingent tax matters primarily related transfer pricing separation Baxalta well need record valuation allowances loss making entities Partially offsetting foregoing adverse factors benefit reaching settlement Puerto Rico excise tax matter well U.S R&D credit resulting retroactive reinstatement December 2015 Protecting Americans Tax Hikes Act 2015 Factors impacting company effective tax rate 2014 included favorable settlement portion company contingent tax matter related operations Turkey well favorable shift earnings high low tax jurisdictions compared prior period Additionally effective tax rate unfavorably impacted increases valuation allowances due tax benefit losses company believe likely realize interest expense related company unrecognized tax benefits The company earns significant amount operating income outside United States substantial portion deemed indefinitely reinvested foreign jurisdictions As result company cash short-term investments held foreign subsidiaries The company intend foresee need repatriate funds expects existing domestic cash short-term investments cash flows operations continue sufficient fund domestic operating activities cash commitments investing financing activities regular quarterly dividends capital expenditures least next 12 months thereafter foreseeable future If company require capital United States generated domestic operations e.g fund significant discretionary activities business acquisitions share repurchases company could elect repatriate future earnings foreign jurisdictions raise capital United States debt equity issuances These alternatives could result higher effective tax rates increased interest expense dilution company earnings The company borrowed domestically continues believe ability reasonable interest rates Income Continuing Operations Earnings per Diluted Share Income continuing operations 5.0 billion 2016 393 million 2015 457 million 2014 Income continuing operations per diluted share 9.01 2016 0.72 2015 0.83 2014 The significant factors events causing net changes 2015 2016 2014 2015 discussed Additionally income continuing operations per diluted share positively impacted repurchase 17.8 million shares cash repurchases equity-for-equity exchange Retained Shares outstanding Baxter shares 2016 repurchase eight million shares 2014 Refer Note 12 Item 8 information regarding company stock repurchases 27 Loss Income Discontinued Operations The following table summary operating results Baxalta reflected discontinued operations years ended December 31 2016 2015 2014 Years ended December 31 millions 2016 2015 2014 Net sales 148 2,895 6,523 Loss income discontinued operations income taxes 10 752 2,562 Gain disposal discontinued operations 19 Income tax expense 10 177 522 Total loss income discontinued operations 1 575 2,040 Refer Note 2 Item 8 additional information regarding separation Baxalta LIQUIDITY AND CAPITAL RESOURCES The company cash flows reflect continuing discontinued operations Cash Flows Operations Continuing Operations Operating cash flows continuing operations totaled 1.6 billion 2016 1.3 billion 2015 1.2 billion 2014 The cash flows continuing operations 2015 impacted receipt 52 million legal settlement well 114 million payments related July 2015 debt tender offer See factors impacting increase cash flows 2016 decrease cash flows 2015 Accounts Receivable Cash flows relating accounts receivable increased 2016 2015 days sales outstanding decreased 2016 increased 2015 Days sales outstanding 54.5 days 56.2 days 54.2 days 2016 2015 2014 respectively Days sales outstanding decreased 2016 primarily driven timing collections certain international markets Days sales outstanding increased 2015 driven slower collections United States Inventories Cash flows relating inventory improved outflow 118 million 2015 inflow 80 million 2016 driven continued working capital improvement initiatives decreased days inventory hand ten days increased turns significantly compared prior year The following summary inventories December 31 2016 2015 well inventory turns segment 2016 2015 2014 Inventory turns year calculated annualized fourth quarter cost sales divided year-end inventory balance Inventories Inventory turns millions except inventory turn data 2016 2015 2016 2015 2014 Renal 544 605 4.4 3.7 3.6 Hospital Products 885 955 3.9 3.6 3.7 Other 1 44 n/a n/a n/a Total company 1,430 1,604 4.1 3.6 3.7 Other The changes accounts payable accrued liabilities outflow 197 million 2016 inflow 236 million 2015 37 million outflow 2014 The change 2016 primarily driven increase tax payments primarily due tax settlement well timing payments suppliers Refer Note 15 Item 8 additional details regarding tax settlement The change 2015 primarily driven timing payments suppliers well timing tax payments Payments related execution SIGMA SPECTRUM infusion pump recalls well company business optimization initiatives 191 million 2016 112 million 2015 124 million 2014 Refer Note 7 Item 8 information regarding SIGMA SPECTRUM infusion pump recalls business optimization initiatives 28 Other balance sheet items net cash inflows 115 million 2016 outflows 341 million 17 million 2015 2014 respectively In 2016 company received U.S federal income tax refund 250 million result carrying back prior tax years company 2015 U.S tax loss arose significant part funding company defined benefit pension plan portion Baxalta retained stake Additionally cash contributions company pension plans totaled 66 million 157 million 74 million 2016 2015 2014 respectively The changes 2015 2014 primarily driven prepaid expenses hedging activity Cash Flows Investing Activities Continuing Operations Capital Expenditures Capital expenditures relating continuing operations totaled 719 million 2016 911 million 2015 925 million 2014 The company capital expenditures 2016 2015 consisted targeted investments projects support production PD IV solutions well expansion activities dialyzers The decline capital expenditures three years due reduction spending related ongoing projects completion certain expansion activities Acquisitions Investments Net cash outflows related acquisitions investments 48 million 2016 34 million 2015 95 million 2014 The cash outflows 2016 driven primarily acquisition rights vancomycin Celerity The cash outflows 2015 driven acquisition rights cefazolin injection GALAXY Container 2g/100mL Celerity The cash outflows 2014 driven acquisitions IC Net International Ltd certain investments Refer Note 5 Item 8 information company significant acquisitions arrangements Divestitures Other Investing Activities Net cash inflows relating divestitures investing activities 37 million 2016 84 million 2015 99 million 2014 The decrease 2015 2016 primarily driven sale certain investments assets 2015 Cash inflows 2014 primarily related proceeds divestiture Baxter legacy CRRT business sale certain investments Cash Flows Financing Activities Debt Issuances Net Payments Obligations Net cash outflows related debt financing obligations totaled 56 million 2016 primarily related 190 million repayment company 0.95 senior unsecured notes matured June 2016 130 million repayment company 5.9 senior unsecured notes matured September 2016 redemption approximately 1 billion aggregate principal amount senior notes September 2016 well repayment short-term obligations The company also 300 million net repayments related commercial paper program These cash outflows partially offset issuances debt totaling 1.6 billion senior notes August 2016 Refer Note 8 Item 8 additional details regarding debt transactions 2016 Net cash inflows related debt financing obligations totaled 2.4 billion 2015 driven approximately 6.9 billion issuances debt primarily related Baxalta senior notes borrowings company revolving credit facilities The company purchased aggregate approximately 2.7 billion principal amount notes 2015 Additionally company repaid 600 million 4.625 senior unsecured notes matured March 2015 borrowings company Euro-denominated revolving credit facility The company issued redeemed commercial paper throughout year 300 million outstanding December 31 2015 Net cash outflows related debt financing obligations totaled 113 million 2014 driven approximately 1 billion repayments included 500 million floating rate senior unsecured notes matured December 2014 well 350 million 4.0 senior unsecured notes matured March 2014 The company issued redeemed commercial paper throughout year 875 million outstanding December 31 2014 The company debt instruments discussed unsecured contain certain covenants including restrictions relating company issuance secured debt 29 Other Financing Activities In connection separation Baxter transferred 2.1 billion cash Baxalta 2015 Cash dividend payments totaled 0.3 billion 2016 0.9 billion 2015 1.1 billion 2014 The decrease cash dividend payments 2016 2015 primarily due decrease quarterly dividend separation Baxalta 0.52 per share quarterly dividends beginning May 2014 0.115 per quarterly dividends beginning July 2015 The Baxter cash dividend increased 0.13 per share quarterly dividends beginning May 2016 Proceeds realized excess tax benefits stock issued employee benefit plans totaled 325 million 200 million 369 million 2016 2015 2014 respectively Total realized excess tax benefits 39 million 2016 7 million 2015 24 million 2014 presented consolidated statements cash flows inflow financing section outflow operating section In 2016 company executed equity-for-equity exchange Retained Shares 11.5 million outstanding Baxter shares As authorized Board Directors company repurchases stock depending company cash flows net debt level market conditions In July 2012 Board Directors authorized repurchase 2.0 billion company common stock The Board Directors increased authority additional 1.5 billion November 2016 The company paid 287 million cash repurchase approximately 6.3 million shares pursuant authority 2016 1.7 billion remaining available authorization December 31 2016 The company repurchase stock 2015 Credit Facilities Access Capital Credit Ratings Credit Facilities As December 31 2016 company U.S dollar-denominated revolving credit facility Euro-denominated senior revolving credit facility maximum capacity 1.5 billion approximately 200 million respectively As December 31 2016 company compliance financial covenants agreements The non-performance financial institution supporting either credit facilities would reduce maximum capacity facilities institution respective commitment Effective July 1 2015 company terminated 1.5 billion U.S dollar-denominated revolving credit facility 300 million Euro-denominated revolving credit facility set mature December 2015 connection separation distribution In connection terminations company entered credit agreements providing senior U.S dollar-denominated revolving credit facility aggregate principal amount 1.5 billion maturing 2020 well Euro-denominated senior revolving credit facility aggregate principal amount 200 million maturing 2020 The company may option seek increase aggregate commitment new U.S facility additional 750 million The new facilities enable company borrow funds unsecured basis variable interest rates contain various covenants including maximum net leverage ratio maximum interest coverage ratio Additionally December 31 2015 company third revolving credit facility maximum capacity 1.8 billion scheduled mature earlier March 28 2016 date commitments facility reduced zero terminated whole pursuant terms thereof On January 27 2016 Baxter exchanged 37.6 million shares Baxalta common stock 1.45 billion aggregate principal amount outstanding revolving credit facility This exchange extinguished outstanding indebtedness facility time facility terminated In connection exchange Baxalta common stock Baxter recognized 1.2 billion realized gains 2016 The company also maintains credit arrangements described Note 8 Item 8 Access Capital The company intends fund short-term long-term obligations mature cash hand future cash flows operations issuing additional debt The company 2.8 billion cash equivalents December 31 2016 adequate cash available meet operating requirements jurisdiction company operates The company invests excess cash certificates deposit money market funds diversifies concentration cash among different financial institutions The company ability generate cash flows operations issue debt enter financing arrangements acceptable terms could adversely affected material decline demand company products solvency 30 customers suppliers deterioration company key financial ratios credit ratings significantly unfavorable changes conditions However company believes sufficient financial flexibility issue debt enter financing arrangements attract long-term capital acceptable terms support company growth objectives The company continues business foreign governments certain countries including Greece Spain Portugal Italy experienced deterioration credit economic conditions As December 31 2016 company net accounts receivable public sector Greece Spain Portugal Italy totaled 137 million While economic conditions significantly impacted company ability collect receivables global economic conditions liquidity issues certain countries resulted may continue result delays collection receivables credit losses Credit Ratings The company credit ratings December 31 2016 follows Standard Poor Fitch Moody Ratings Senior debt A BBB Baa2 Short-term debt A2 F2 P2 Outlook Stable Stable Stable Contractual Obligations As December 31 2016 company contractual obligations excluding accounts payable accrued liabilities payable maturing following periods millions Total Less one year One three years Three five years More five years Long-term debt capital lease obligations including current maturities 2,794 3 6 700 2,085 Interest short long-term debt capital lease obligations 1 1,496 84 169 163 1,080 Operating leases 663 129 193 125 216 Other long-term liabilities2 443 114 43 286 Purchase obligations3 450 275 153 20 2 Contractual obligations4 5,846 491 635 1,051 3,669 1 Interest payments debt capital lease obligations calculated future periods using interest rates effect end 2016 Projected interest payments include related effects interest rate swap agreements Certain projected interest payments may differ future based changes floating interest rates foreign currency fluctuations factors events The projected interest payments pertain obligations agreements outstanding December 31 2016 Refer Note 8 Note 9 Item 8 discussion regarding company debt instruments related interest rate agreements outstanding December 31 2016 2 The primary components long-term liabilities company consolidated balance sheet liabilities relating pension postemployment benefit plans litigation foreign currency hedges The company projected timing future cash payments based contractual maturity dates applicable estimates timing payments liabilities contractual maturity dates The actual timing payments could differ estimates The company contributed 772 million 157 million 74 million defined benefit pension plans 2016 2015 2014 respectively The timing funding future uncertain dependent future movements interest rates investment returns changes laws regulations variables Therefore table excludes pension plan cash outflows The pension plan balance included long-term liabilities excluded table totaled 1.5 billion December 31 2016 3 Includes company significant contractual unconditional purchase obligations For cancelable agreements penalty due upon cancellation included These commitments exceed company projected requirements normal course business Examples include firm commitments raw material purchases utility agreements service contracts 31 4 Excludes contingent liabilities uncertain tax positions These amounts excluded contractual obligations due uncertainty regarding timing amount future payments Refer Notes 10 11 Item 8 additional information regarding commitments Off-Balance Sheet Arrangements Baxter periodically enters off-balance sheet arrangements Certain contingencies arise normal course business recorded consolidated balance sheet accordance GAAP contingent joint development commercialization arrangement payments Also upon resolution uncertainties company may incur charges excess presently established liabilities certain matters contractual indemnifications For discussion company significant off-balance sheet arrangements refer Note 10 Item 8 information regarding receivable securitizations Note 11 Item 8 regarding joint development commercialization arrangements indemnifications Note 16 Item 8 regarding legal contingencies FINANCIAL INSTRUMENT MARKET RISK The company operates global basis exposed risk earnings cash flows equity could adversely impacted fluctuations foreign exchange interest rates The company hedging policy attempts manage risks acceptable level based company judgment appropriate trade-off risk opportunity costs Refer Note 9 Note 10 Item 8 information regarding company financial instruments hedging strategies Currency Risk The company primarily exposed foreign exchange risk respect revenues generated outside United States denominated Euro British Pound Chinese Yuan Korean Won Australian Dollar Canadian Dollar Japanese Yen Colombian Peso Brazilian Real Swedish Krona Mexican Peso New Zealand Dollar The company manages foreign currency exposures consolidated basis allows company net exposures take advantage natural offsets In addition company uses derivative nonderivative financial instruments reduce net exposure foreign exchange Gains losses hedging instruments offset losses gains hedged transactions reduce earnings stockholders equity volatility relating foreign exchange Financial market currency volatility may limit company ability cost-effectively hedge exposures The company may use options forwards cross-currency swaps hedge foreign exchange risk earnings relating forecasted transactions denominated foreign currencies recognized assets liabilities The maximum term company cash flow hedge contracts place related forecasted transactions December 31 2016 12 months The company also enters derivative instruments hedge certain intercompany third-party receivables payables debt denominated foreign currencies Currency restrictions enacted Venezuela require Baxter obtain approval Venezuelan government exchange Venezuelan bolivars U.S dollars require exchange made official exchange rate established government In first quarter 2016 Venezuelan government moved three-tier exchange rate system two-tiered exchange rate system official rate food medicine imports adjusted 6.3 10 bolivars per U.S dollar This devaluation resulted charge 9 million first quarter 2016 As December 31 2016 company exposure Venezuelan operations approximately 12 million As part risk-management program company performs sensitivity analyses assess potential changes fair value foreign exchange instruments relating hypothetical reasonably possible near-term movements foreign exchange rates A sensitivity analysis changes fair value foreign exchange option forward contracts outstanding December 31 2016 predictive nature indicated U.S Dollar uniformly weakened 10 currencies net-of-tax basis net asset balance 13 million respect contracts would decrease 34 million resulting net liability position A similar analysis performed respect option forward contracts outstanding December 31 2015 indicated net-of-tax basis net asset balance 5 million would decrease 17 million The sensitivity analysis model recalculates fair value foreign exchange option forward contracts outstanding December 31 2016 replacing actual exchange rates December 31 2016 exchange rates 10 weaker compared actual exchange rates applicable currency All factors held constant These sensitivity analyses disregard possibility currency exchange rates move opposite directions gains one currency may may offset 32 losses another currency The analyses also disregard offsetting change value underlying hedged transactions balances Interest Rate Other Risks The company also exposed risk earnings cash flows could adversely impacted fluctuations interest rates The company policy manage interest costs using mix fixed floating-rate debt company believes appropriate To manage mix cost-efficient manner company periodically enters interest rate swaps company agrees exchange specified intervals difference fixed floating interest amounts calculated reference agreed-upon notional amount The company also periodically uses forward-starting interest rate swaps treasury rate locks hedge risk earnings associated fluctuations interest rates relating anticipated issuances term debt As part risk management program company performs sensitivity analyses assess potential gains losses earnings relating hypothetical movements interest rates A 19 basis-point increase interest rates approximately 10 company weighted-average interest rate 2016 affecting company financial instruments including debt obligations related derivatives would immaterial effect company 2016 2015 2014 earnings fair value company fixed-rate debt end fiscal year With respect company investments affiliates company believes reasonably possible near-term losses earnings cash flows fair values would material company consolidated financial position CHANGES IN ACCOUNTING STANDARDS Refer Note 1 Item 8 information changes accounting standards CRITICAL ACCOUNTING POLICIES The preparation financial statements accordance GAAP requires company make estimates judgments affect reported amounts assets liabilities revenues expenses A summary company significant accounting policies included Note 1 Item 8 Certain company accounting policies considered critical policies important depiction company financial statements require significant difficult complex judgments company often requiring use estimates effects matters inherently uncertain Actual results differ company estimates could unfavorable effect company results operations financial position The following summary accounting policies company considers critical consolidated financial statements Revenue Recognition Related Provisions Allowances The company policy recognize revenues product sales services earned Specifically revenue recognized persuasive evidence arrangement exists delivery occurred services rendered price fixed determinable collectability reasonably assured For product sales revenue recognized title risk loss transferred customer The shipping terms majority company revenue arrangements FOB destination The company sometimes enters arrangements commits delivering multiple products services customers In cases total arrangement consideration allocated deliverables based relative selling prices Then allocated consideration recognized revenue accordance principles described Selling prices determined applying selling price hierarchy Selling prices determined using vendor specific objective evidence VSOE exists Otherwise selling prices determined using third party evidence TPE If neither VSOE TPE available company uses best estimate selling prices Provisions rebates chargebacks wholesalers distributors returns discounts collectively sales deductions provided time related sales recorded reflected reduction sales The sales deductions based primarily estimates amounts earned claimed sales The company periodically systematically evaluates collectability accounts receivable determines appropriate reserve doubtful accounts In determining amount reserve company considers historical credit losses past-due status receivables payment history customer-specific information relevant factors considerations The company also provides estimated costs may incurred warranty programs cost probable reasonably estimable time related revenue recognized The cost determined based actual company experience similar products well relevant information Estimates future costs company 33 warranty programs could change based developments future The company able estimate probability amount future developments could impact reserves believes presently established reserves adequate Pension Other Postemployment Benefit OPEB Plans The company provides pension postemployment benefits certain employees These employee benefit expenses reported line items consolidated income statement applicable employee compensation expense The valuation funded status net periodic benefit cost plans calculated using actuarial assumptions These assumptions reviewed annually revised appropriate The significant assumptions include following interest rates used discount pension OPEB plan liabilities long-term rate return pension plan assets rates increases employee compensation used estimating liabilities anticipated future healthcare trend rates used estimating OPEB plan liability assumptions involving demographic factors retirement mortality turnover used estimating liabilities Selecting assumptions involves analysis short-term long-term historical trends known economic market conditions time valuation also called measurement date The use different assumptions would result different measures funded status net cost Actual results future could differ expected results The company able estimate probability actual results differing expected results believes assumptions appropriate The company key assumptions listed Note 13 Item 8 The critical assumptions relate plans covering U.S Puerto Rico employees plans significant company consolidated financial statements Discount Rate Assumption Effective December 31 2016 measurement date company utilized discount rates 4.09 3.89 measure benefit obligations U.S Puerto Rico pension plans OPEB plan respectively The company used broad population approximately 200 Aa-rated corporate bonds December 31 2016 determine discount rate assumption All bonds denominated U.S Dollars minimum amount outstanding 50 million This population bonds narrowed broader universe approximately 700 Moody Aa rated non-callable callable make-whole provisions bonds eliminating top 10th percentile bottom 40th percentile adjust pricing anomalies represent bonds Baxter would likely select actually annuitize pension OPEB plan liabilities This portfolio bonds used generate yield curve associated spot rate curve discount projected benefit payments U.S Puerto Rico plans The discount rate single level rate produces result spot rate curve For plans Canada Japan United Kingdom Eurozone company uses method essentially described U.S Puerto Rico plans For company international plans discount rate generally determined reviewing country region-specific government corporate bond interest rates To understand impact changes discount rates pension OPEB plan cost company performs sensitivity analysis Holding assumptions constant 50 basis point i.e one-half one percent increase discount rate global pre-tax pension OPEB plan cost would decrease approximately 36 million 50 basis point decrease discount rate global pre-tax pension OPEB plan cost would increase approximately 40 million Effective January 1 2016 company changed approach used calculate service interest components net periodic benefit cost Previously company calculated service interest components utilizing single weighted-average discount rate derived yield curve used measure benefit obligation The company elected alternative approach utilizes full yield curve approach estimation components applying specific spot rates along yield curve used determination benefit obligation underlying projected cash flows The company believes approach provides precise measurement service interest costs improving correlation projected benefit cash flows corresponding spot rates The company accounted change prospectively change estimate As result change service cost interest cost plans reduced 40 million 2016 compared previous method 34 Return Plan Assets Assumption In measuring net periodic cost 2016 company used long-term expected rate return 7.00 pension plans covering U.S Puerto Rico employees This assumption decrease 6.50 2017 This assumption applicable company OPEB plan funded The company establishes long-term asset return assumption based review historical compound average asset returns company-specific relating broad market based company asset allocation well analysis current market economic information future expectations The current asset return assumption supported historical market experience company actual targeted asset allocation In calculating net pension cost expected return assets applied calculated value plan assets recognizes changes fair value plan assets systematic manner five years The difference expected return actual return plan assets component total net unrecognized gain loss subject amortization future To understand impact changes expected asset return assumption net cost company performs sensitivity analysis Holding assumptions constant 50 basis point increase decrease asset return assumption global pre-tax pension plan cost would decrease increase approximately 22 million Other Assumptions For U.S Puerto Rico plans beginning December 31 2014 measurement date company used RP 2014 combined mortality table adjusted reflect Baxter specific past experience improvements projected using generational BB-2D projection scale adjusted long term improvement 0.8 2027 For pension plans company utilized country region-specific mortality tables calculate plans benefit obligations The company periodically analyzes updates assumptions concerning demographic factors retirement mortality turnover considering historical experience well anticipated future trends The assumptions relating employee compensation increases future healthcare costs based historical experience market trends anticipated future company actions Refer Note 13 Item 8 information regarding sensitivity OPEB plan obligation total service interest cost components OPEB plan cost potential changes future healthcare trend rates Legal Contingencies The company involved product liability patent commercial regulatory legal proceedings arise normal course business Refer Note 16 Item 8 information The company records liability loss considered probable amount reasonably estimated If reasonable estimate probable loss range amount within range better estimate minimum amount range accrued If loss probable probable loss cannot reasonably estimated liability recorded The company established reserves certain legal matters At December 31 2016 total legal liabilities 53 million The company loss estimates generally developed consultation outside counsel based analyses potential outcomes With respect recording insurance recoveries completing assessment accounting company legal contingencies company separately independently analyzes insurance coverage records insurance recoveries probable occurring gross amount expected collected In performing assessment company reviews available information including historical company-specific market collection experience similar claims current facts circumstances pertaining particular insurance claim financial viability applicable insurance company companies relevant information While liability company connection certain claims cannot estimated although resolution reporting period one matters could significant impact company results operations cash flows period outcome legal proceedings expected material adverse effect company consolidated financial position While company believes valid defenses matters litigation inherently uncertain excessive verdicts occur company may future incur material judgments enter material settlements claims Deferred Tax Asset Valuation Allowances Reserves Uncertain Tax Positions The company maintains valuation allowances unless likely portion deferred tax asset realized Changes valuation allowances included company tax provision period change In determining whether valuation allowance warranted company evaluates factors prior earnings history expected future earnings carryback 35 carryforward periods tax strategies could potentially enhance likelihood realization deferred tax asset The realizability assessments made given balance sheet date subject change future particularly earnings subsidiary significantly higher lower expected company takes operational tax planning actions could impact future taxable earnings subsidiary In normal course business company audited federal state foreign tax authorities periodically challenged regarding amount taxes due These challenges relate timing amount deductions allocation income among various tax jurisdictions The company believes tax positions comply applicable tax law company intends defend positions In evaluating exposure associated various tax filing positions company records reserves uncertain tax positions accordance GAAP based technical support positions company past audit experience similar situations potential interest penalties related matters The company results operations effective tax rate given period could impacted upon final resolution taxing authorities company prevailed positions reserves established required pay amounts excess established reserves Valuation Intangible Assets Including IPR&D The company acquires intangible assets records fair value Valuations generally completed business acquisitions using discounted cash flow analysis incorporating stage completion consideration market participant assumptions The significant estimates assumptions inherent discounted cash flow analysis include amount timing projected future cash flows discount rate used measure risks inherent future cash flows assessment asset life cycle competitive trends impacting asset including consideration technical legal regulatory economic factors Each factors assumptions significantly affect value intangible asset Acquired in-process R&D IPR&D value assigned acquired technology products development received regulatory approval alternative future use Acquired IPR&D included business combination capitalized indefinite-lived intangible asset Development costs incurred acquisition expensed incurred Upon receipt regulatory approval related technology product indefinite-lived intangible asset accounted finite-lived intangible asset amortized straight-line basis estimated useful life If R&D project abandoned indefinite-lived asset charged expense R&D acquired transactions business combinations expensed immediately For transactions payments made third parties regulatory approval capitalized amortized remaining useful life related asset classified intangible assets Due inherent uncertainty associated R&D projects assurance actual results differ materially underlying assumptions used prepare discounted cash flow analyses R&D project result successful commercial product Impairment Assets Goodwill indefinite-lived intangible assets subject impairment reviews annually whenever indicators impairment exist The company assesses goodwill impairment based reporting units operating segments Renal Hospital Products As December 31 2016 date company annual impairment review fair value company reporting units excess carrying values The company performs qualitative assessment indefinite-lived intangible assets including IPR&D least annually If intangible asset determined likely impaired result assessment company completes quantitative impairment test Intangible assets definite lives long-lived assets fixed assets reviewed impairment whenever events changes circumstances indicate carrying amount asset may recoverable Refer Note 1 Item 8 information The company impairment reviews based estimated future cash flow approach requires significant judgment respect future volume revenue expense growth rates changes working capital use foreign currency exchange rates selection appropriate discount rate asset groupings assumptions estimates The estimates assumptions used consistent company business plans applicable market participant views company similar companies The use alternative estimates assumptions could increase decrease estimated fair values assets potentially result different impacts company results operations Actual results may differ company estimates Stock-Based Compensation Plans Stock-based compensation cost estimated grant date based fair value award cost recognized expense ratably substantive vesting period The company stock compensation costs primarily relate awards stock 36 options restricted stock units RSUs performance share units PSUs The company uses Black-Scholes model estimating fair value stock options significant assumptions include long-term projections regarding stock price volatility employee exercise post-vesting termination pre-vesting forfeiture behaviors interest rates dividend yields The company expected volatility assumption based weighted-average historical volatility Baxter stock implied volatility traded options Baxter stock historical volatility heavily weighted The expected life assumption primarily based vesting terms stock option historical employee exercise patterns employee post-vesting termination behavior The risk-free interest rate expected life option based U.S Treasury yield curve effect time grant The dividend yield reflects historical experience well future expectations expected life option The fair value RSUs equal quoted price company common stock date grant PSUs granted 2016 based either adjusted operating margin return invested capital ROIC based upon Baxter stock performance relative company peer group The vesting condition PSUs based adjusted operating margin ROIC annual performance targets set beginning year tranche award three-year service period The holder adjusted operating margin ROIC PSUs entitled receive number shares common stock equal percentage ranging 0 200 adjusted operating margin ROIC PSUs granted depending actual results compared annual performance targets results may adjusted individual performance Compensation cost adjusted operating margin ROIC PSUs measured based fair value awards date specific vesting terms tranche award established The fair value awards determined based quoted price company stock grant date tranche award The compensation cost adjusted operating margin ROIC PSUs adjusted reporting date reflect estimated probability achieving adjusted operating margin ROIC vesting condition The probability achieving operating margin vesting condition compensation cost adjusted reflect 200 attainment year ended December 31 2016 The vesting condition PSUs based Baxter stock performance relative company peer group fair valued using Monte Carlo model A Monte Carlo model uses stock price volatility variables estimate probability satisfying market conditions resulting fair value award Refer Note 12 Item 8 additional information CERTAIN REGULATORY MATTERS In January 2014 company received Warning Letter FDA primarily directed quality systems company Round Lake Illinois facility particularly facility capacity specification developer certain company medical devices This Warning Letter lifted February 2017 The company received Warning Letter December 2013 included observations related company ambulatory infuser business Irvine California previously subject agency action In June 2013 company received Warning Letter FDA regarding operations processes North Cove North Carolina Jayuya Puerto Rico facilities November 2015 attended Regulatory Meeting FDA concerning Jayuya facility The Warning Letter addresses observations related Current Good Manufacturing Practice CGMP violations two facilities In June 2010 company received Warning Letter FDA connection inspection McGaw Park Illinois facility previously supported Renal franchise The company Round Lake facility provides related capacity Renal franchise The Warning Letter pertains processes company analyzes addresses product complaints corrective preventative action reports relevant information FDA This Warning Letter lifted February 2017 On October 9 2014 company Regulatory Meeting FDA discuss Warning Letters described At meeting company agreed work closely FDA provide regular updates progress meet requirements resolve matters identified Warning Letters described Refer Item 1A Annual Report Form 10-K additional discussion regulatory matters may impact company FORWARD-LOOKING INFORMATION This annual report includes forward-looking statements Use words may would could believes estimates projects potential expects plans seeks intends evaluates pursues anticipates continues designs impacts affects forecasts target outlook initiative objective designed priorities goal negative words similar expressions intended identify forward-looking statements represent current judgment possible future events These forward-looking statements may include statements respect accounting estimates 37 assumptions litigation-related matters including outcomes future regulatory filings company R&D pipeline strategic objectives credit exposure foreign governments potential developments respect credit ratings investment foreign earnings estimates liabilities including related uncertain tax positions contingent payments future pension plan contributions costs discount rates rates return company exposure financial market volatility foreign currency interest rate risks potential tax liability associated separation company biopharmaceuticals medical products businesses including 2016 disposition company retained stake Baxalta impact competition future sales growth business development activities business optimization initiatives cost saving initiatives future capital R&D expenditures future debt issuances manufacturing expansion sufficiency company facilities financial flexibility adequacy credit facilities tax provisions reserves effective tax rate statements relate historical facts These forward-looking statements based certain assumptions analyses made light company experience perception historical trends current conditions expected future developments well factors company believes appropriate circumstances While statements represent company current judgment future may hold company believes judgments reasonable statements guarantees events financial results Whether actual future results developments conform expectations predictions subject number risks uncertainties including following factors many beyond control failure achieve long-term financial improvement goals demand market acceptance risks competitive pressures related new existing products impact products quality patient safety concerns product development risks including satisfactory clinical performance ability manufacture appropriate scale general unpredictability associated product development cycle product quality patient safety issues leading product recalls withdrawals launch delays sanctions seizures litigation declining sales future actions FDA EMA regulatory body government authority could delay limit suspend product development manufacturing sale result seizures recalls injunctions monetary sanctions criminal civil liabilities failures respect company compliance programs future actions third parties including third-party payers healthcare reform similar measures implemented modified repealed United States globally impact ongoing U.S healthcare reform similar actions undertaken foreign governments respect pricing reimbursement taxation rebate policies additional legislation regulation governmental pressures United States globally may affect pricing reimbursement taxation rebate policies government agencies private payers elements company business impact competitive products pricing including generic competition drug reimportation disruptive technologies global regulatory trade tax policies company ability identify business development growth opportunities successfully execute business development strategies company ability finance develop new products enhancements commercially acceptable terms availability pricing acceptable raw materials component supply inability create additional production capacity timely manner occurrence manufacturing supply difficulties ability protect enforce company owned in-licensed patent proprietary rights including trademarks copyrights trade secrets know-how patents third parties preventing restricting company manufacture sale use affected products technology impact future tax liability respect separation distribution including respect disposition Retained Shares 38 failure Baxalta Shire satisfy obligation separation agreements including tax matters agreement Letter Agreement impact global economic conditions company customers suppliers including foreign governments certain countries company operates fluctuations foreign exchange interest rates changes law concerning taxation income including income earned outside United States may part comprehensive tax reform actions tax authorities connection ongoing tax audits breaches failures company information technology systems loss key employees inability identify recruit new employees outcome pending future litigation adequacy company cash flows operations meet ongoing cash obligations fund investment program factors identified elsewhere Annual Report Form 10-K including factors described Item 1A filings Securities Exchange Commission available company website Actual results may differ materially projected forward-looking statements The company undertake update forward-looking statements Item 7A Quantitative Qualitative